|  |  |
| --- | --- |
|  | **NHS Prescription Services**  Bridge House  152 Pilgrim Street  Newcastle upon Tyne  NE1 6SN  0845 850 0001  Email:[nhsbsa.prescriptionservices@nhsbsa.nhs.uk](mailto:nhsbsa.prescriptionservices@nhsbsa.nhs.uk)  Website:[www.nhsbsa.nhs.uk](http://www.nhsbsa.nhs.uk)  10 Feb 2025 |
|  |

VERSION 2.1.0

Dear dm+d User,

**IMPORTANT NOTICE**: **Addition of 'Ingredients for VTMs' in dm+d (XML) release files and SNOMED CT UK Drug Extension**

The addition of ‘Ingredients for VTMs’ enhancement work has been carried out.

**\*\*\*An issue has been identified which may impact users of dm+d\*\*\***

VTMs with an International SNOMED identifier for a “contains only” Medicinal product concept must also have an International SNOMED identifier. However, there are a small number of ingredient concepts with a SNOMED CT UK Extension identifier in dm+d and an International identifier in the SNOMED CT UK Drug Extension, leading to misalignment between these VTM concepts in dm+d and the SNOMED CT UK Drug Extension.

**List of affected concepts**

See appendix XXVI of the [dm+d Editorial Policy](https://www.nhsbsa.nhs.uk/sites/default/files/2024-10/Editorial%20Policy%20R2%20v4.0%20October%202024.docx).This will be updated to include ‘Perflutren’.

**Potential impact for users of dm+d:**

dm+d Editorial Policy does not permit SNOMED identifiers to be re-used or reassigned, even where the concept identifier has been subsequently updated in dm+d. This means we are unable to assign ingredients in dm+d for the affected VTMs.

**Proposed solution:**

Create ingredient concepts within dm+d with a UK Extension identifier.

This UK Extension identifier would be inactive in the SNOMED CT UK Drug Extension with a SAME\_AS relationship to the International identifier concept.

**Action for system suppliers:**

Prior to actioning this fix, we would like to understand the potential impact to system suppliers on the possible re-use of these particular codes on a case by case scenario. A worked example is included below.

In order to present this issue and the impact on change of policy (to system suppliers) to the next dm+d Content Committee in February we would be grateful if you would:

* email [dmdenquiries@nhsbsa.nhs.uk](mailto:dmdenquiries@nhsbsa.nhs.uk)
* by close of business on ***Friday 14th February***
* Stating - ***supplier details*** and ***impact to your system and users***
* Please use the reference ‘***Impact of re-use of Identifiers’*** in the email header

**Worked example:**

|  |  |  |
| --- | --- | --- |
| **Ingredient** | **dm+d concept ID** | **Status** |
| Sevelamer hydrochloride | 395871000 Sevelamer (substance) International ID  From 08/2005 until 12/2010 | History – previous ID |
| 18308811000001104 - UK extension ID  From 12/2010 to date | Current |
| Sevelamer | 18308711000001107 – UK extension ID  From 12/2010 to date | Current |

In SNOMED UK Drug Extension:

395871000 Sevelamer (substance) – Active

18308811000001104 - Inactive

18308711000001107 – Inactive

The correct international identifier for the ingredient Sevelamer is 395871000 but this cannot be assigned as it was used between 2005 and 2010 and is part of the historical information for the ingredient Sevelamer hydrochloride.

What would be the impact upon your system and users **IF** the ingredient Sevelamer (or any of the other examples in the appendix) was assigned the international ID.

The NHSBSA/NHSE Terminology teams thank-you for your valuable feedback.

**Vyxeos liposomal 44mg/100mg powder for concentrate for solution for infusion vials**

As per TRUD communication version 1.2.0 (dated 13/01/2025), the previous dm+d records for the above product were invalidated and reauthored (along with a new VTM).

The reauthoring of these historical VTM and VMP records was required as they do not reflect the product’s liposomal characteristics.

Please note that this reauthoring is not due to any safety concerns or change in formulation for the above product, Vyxeos.

**SNOMED International Proposal to Increase Description Length Limit**

We are providing an update to the [information previously communicated](https://nhsengland.kahootz.com/t_c_home/viewBlogArticle?articleID=1108441&nextURL=%2Ft_c_home%2FviewBlog%3Fblogid%3D50136) regarding the proposal from SNOMED International to increase the maximum length of Fully Specified Name and Synonym descriptions,.

SNOMED International have provided [further information](https://nhsengland.kahootz.com/t_c_home/viewBlogArticle?articleID=1154361&nextURL=%2Ft_c_home%2FviewBlog%3Fblogid%3D50136) about the [proposal to increase description length limit](https://nhsengland.kahootz.com/t_c_home/viewBlogArticle?articleID=1108441&nextURL=%2Ft_c_home%2FviewBlog%3Fblogid%3D50136) from 255 to 4096 characters.

NHS England are currently assessing whether this proposed change will impact Fully Specified Names (FSN) created in the SNOMED CT UK Drug Extension. NHS England do not expect that this proposed change will impact Preferred Terms (PT) in the SNOMED CT UK Drug Extension.

This proposal will impact UK users of the **Medicinal Product Hierarchy of the SNOMED International Edition** (both SNOMED CT International Edition and SNOMED CT UK Edition release packages) but dm+d will NOT be affected and we have no plans to adopt these changes.

The planned implementation date for **SNOMED International** **changes is January 2026** and will come into effect in the **April 2026 UK release**.

Any concerns or queries should be directed to SNOMED International at [release@snomed.org](mailto:release@snomed.org). Please cc [information.standards@nhs.net](mailto:information.standards@nhs.net) to enable NHS England to have visibility of UK stakeholder feedback.

**Addition of 'Ingredients for VTMs' in dm+d (XML) release files and SNOMED CT UK Drug Extension**

We are providing an update to information posted in [September](https://nhsengland.kahootz.com/t_c_home/viewBlogArticle?articleID=1113177&nextURL=%2Ft_c_home%2FviewBlog%3Fblogid%3D50136) regarding the addition of 'Ingredients for VTMs' in dm+d (XML) release files and SNOMED CT UK Drug Extension.

The VTM Ingredient XML file will be maintained from Monday 18 November and the VTM Ingredients that need populating will be gradually added over a period of time.  We will provide confirmation when this has been completed.

The weekly dm+d extract will be added to TRUD and the NHS Terminology Server as usual and will include the live VTM Ingredients XML file.

**Please note that VTM Ingredients information will only be available via TRUD and the NHS England Terminology Server from 23 September 2024 and will not be seen in the dm+d browser until further notice is provided.**

Additional information about the change is available on the following [webpage](https://digital.nhs.uk/services/terminology-and-classifications/uk-medicines-terminology-futures/changes-to-digital-terminologies/addition-of-ingredients-for-vtms-in-dm-d-xml-release-files-and-snomed-ct-uk-drug-extension).

If you have any specific queries relating to the dm+d and SNOMED CT UK Drug Extension changes, please contact [nhsdigital.ukmeds@nhs.net](mailto:nhsdigital.ukmeds@nhs.net)

**Monthly dm+d Supplier Workshop**

NHS England hosts a monthly workshop for IT system suppliers to discuss dm+d content and implementation queries.  It is an opportunity to speak with colleagues from NHS England and the NHSBSA who manage the terminology.

If you are a system supplier who is interested in joining the group, please contact [medicinestandards@nhs.net](mailto:medicinestandards@nhs.net) for more information.

**DHSC require these concepts to be made available and visible (similar to licensed medicines) in prescribing and dispensing systems for the time being.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Specials/Imports added at request of DHSC to mitigate shortages in the supply chain** | | | |
| **AMP Name** | **AMP SNOMED Code** | **Import/Special** | **dm+d extract date** |
| Desmopressin 150micrograms/dose nasal spray | 38955011000001100 | Imported | 14/09/2020 |
| Desmopressin 150micrograms/dose nasal spray | 38996011000001101 | Special Order | 21/09/2020 |
| Capsaicin 0.025% cream | 41539411000001105 | Imported | 27/03/2023 |
| Capsaicin 0.075% cream | 41540711000001105 | Imported | 27/03/2023 |
| Griseofulvin 125mg tablets | 42441511000001104 | Imported (United States) | 27/11/2023 |
| Griseofulvin 500mg tablets | 42441811000001101 | Imported (United States) | 27/11/2023 |
| Hydrogen peroxide 3% solution | 42510811000001109 | Imported | 18/12/2023 |
| Cerium nitrate hexahydrate 22mg/g / Sulfadiazine silver 10mg/g cream | 42991011000001101 | Imported | 01/07/2024 |
| Sulfadiazine silver 1% cream | 42990711000001107 | Imported | 01/07/2024 |
| Creon 10000 capsules | 43034611000001101 | Imported | 15/07/2024 |
| Creon 25000 capsules | 43034811000001102 | Imported | 15/07/2024 |
| Pancreaze Delayed-Release capsules | 43035111000001108 | Imported | 15/07/2024 |
| Ipratropium bromide 250micrograms/1ml nebuliser liquid unit dose vials | 43093511000001105 | Imported | 22/07/2024 |
| Ipratropium bromide 500micrograms/2ml nebuliser liquid unit dose vials | 43094411000001109 | Imported | 22/07/2024 |
| Methylphenidate 18mg modified-release tablets | 43210911000001100 | Imported | 02/09/2024 |
| Methylphenidate 27mg modified-release tablets | 43211511000001100 | Imported | 02/09/2024 |
| Methylphenidate 36mg modified-release tablets | 43211911000001107 | Imported | 02/09/2024 |
| Methylphenidate 54mg modified-release tablets | 43212411000001109 | Imported | 02/09/2024 |
| Pangrol 10,000 capsules | 43788211000001100 | Imported | 23/09/2024 |
| Pangrol 25,000 capsules | 43788511000001102 | Imported | 23/09/2024 |
| Imiquimod 5% cream 250mg sachets | 41526711000001106 | Imported | 02/12/2024 |

**Invalidation****s**

None

**Advance Notice of Invalidations**

The following concept will be invalidated mid-February as it was added erroneously.

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP** Daunorubicin 44mg / Cytarabine 100mg powder for solution for infusion vials | **VMP** Daunorubicin liposomal 44mg / Cytarabine liposomal 100mg powder for solution for infusion vials |
| **VMP SNOMED ID** 35812911000001103 | **VMP SNOMED ID** 44196811000001108 |
| **VMPP** 1 vial | **VMPP** 1 vial |
| **VMPP SNOMED ID** 35778211000001100 | **VMPP SNOMED ID** 44195211000001101 |
| **AMP** Vyxeos liposomal 44mg/100mg powder for concentrate for solution for infusion vials (Jazz Pharmaceuticals UK Ltd) | **AMP** Vyxeos liposomal 44mg/100mg powder for concentrate for solution for infusion vials (Jazz Pharmaceuticals UK Ltd) |
| **AMP SNOMED ID**  35778311000001108 | **AMP SNOMED ID** 44195311000001109 |
| **AMPP** 1 vial | **AMPP** 1 vial |
| **AMPP SNOMED ID** 35778411000001101 | **AMPP SNOMED ID** 44195411000001102 |

The following concept will be invalidated mid-March as it was added erroneously.

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP** Amikacin 500mg/2ml solution for injection vials (not to be made invalid) | **VMP** Amikacin 500mg/2ml solution for injection ampoules |
| **VMP SNOMED ID** 35899911000001109 | **VMP SNOMED ID**  44422511000001103 |
| **VMPP** 5 vials (not to be made invalid) | **VMPP** 5 ampoule |
| **VMPP SNOMED ID** 4500011000001105 | **VMPP SNOMED ID** 44374911000001108 |
| **AMP** Amikacin 500mg/2ml solution for injection vials (Kent Pharma (UK) Ltd) | **AMP** Amikacin 500mg/2ml solution for injection ampoules (Kent Pharma (UK) Ltd) |
| **AMP SNOMED ID** 42788511000001107 | **AMP SNOMED ID** 44375011000001108 |
| **AMPP** 5 vials | **AMPP** 5 ampoule |
| **AMPP SNOMED ID** 42788611000001106 | **AMPP SNOMED ID** 44375111000001109 |

dm+d Authoring Team